Amerikanische Gesellschaft für Hirudotherapie

Center for Examinations and Tests in Health Service — Republic of Belarus

RCEMTH · Belarus · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Belarus's Republican Center for Examinations and Tests in Health Service (Ministry of Health) — under Belarusian law leeches have been used historically in clinical and traditional practice; the exact contemporary regulatory pathway has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Belarus
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Belarusian Law on Healthcare (No. 2435-XII, as amended)
  • Belarusian Law on Circulation of Medicines (No. 161-Z)
  • Belarusian national medical device regulatory framework

Prescriber Requirements

  • Belarusian Ministry of Health–licensed physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

RCEMTH registration as applicable; Russian and Belarusian-language labelling. Standard cold-chain conditions; cross-border movement subject to Eurasian Economic Union (EAEU) harmonisation.

Import/Export Rules

Ministry of Health import authorisation; veterinary services clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana. EAEU customs procedures apply.

Reimbursement Context

Coverage under the public healthcare system varies by setting; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; in practice Belarus shares regulatory conventions with Russia (Roszdravnadzor) under the EAEU framework. Hirudotherapy has historical clinical recognition in the post-Soviet space; the exact statutory pathway has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.